Last reviewed · How we verify
ESO and pritelivir
ESO and pritelivir is a Small molecule drug developed by AiCuris Anti-infective Cures AG. It is currently in Phase 1 development.
At a glance
| Generic name | ESO and pritelivir |
|---|---|
| Sponsor | AiCuris Anti-infective Cures AG |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ESO and pritelivir CI brief — competitive landscape report
- ESO and pritelivir updates RSS · CI watch RSS
- AiCuris Anti-infective Cures AG portfolio CI
Frequently asked questions about ESO and pritelivir
What is ESO and pritelivir?
ESO and pritelivir is a Small molecule drug developed by AiCuris Anti-infective Cures AG.
Who makes ESO and pritelivir?
ESO and pritelivir is developed by AiCuris Anti-infective Cures AG (see full AiCuris Anti-infective Cures AG pipeline at /company/aicuris-anti-infective-cures-ag).
What development phase is ESO and pritelivir in?
ESO and pritelivir is in Phase 1.
Related
- Manufacturer: AiCuris Anti-infective Cures AG — full pipeline
- Compare: ESO and pritelivir vs similar drugs
- Pricing: ESO and pritelivir cost, discount & access